Revenue Recognition - Additional Information (Details)		3 Months Ended		6 Months Ended
	Nov. 22, 2020 USD ($) Program	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Deferred revenue, revenue recognized		$ 22,303,000	$ 14,780,000	$ 40,599,000	$ 27,676,000
Percentage of revenue expected to be recognized		70.00%		70.00%
Unsatisfied performance obligation		$ 24,617,000		$ 24,617,000
Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Contract with customers, payment terms				60 days
Minimum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Contract with customers, payment terms				30 days
Agreement with Gates Ventures, LLC
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Software contribution revenue related to agreement cover period start date				Jun. 23, 2020
Software contribution revenue related to agreement cover period end date				Jun. 22, 2023
Software contribution revenue recognition				$ 1,000,000
Deferred revenue		0		0
Agreement with Gates Ventures, LLC | First Anniversary
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Software contribution revenue recognition				1,000,000
Agreement with Gates Ventures, LLC | Second Anniversary
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Software contribution revenue recognition				1,000,000
Agreement with Gates Ventures, LLC | Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Software contribution revenue recognition amount				3,000,000
Agreement with Gates Ventures, LLC | Accounts Receivable
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Software contribution revenue recognition				1,000,000
Collaboration and License Agreement | BMS
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Upfront fee received	$ 55,000,000
Maximum milestone payments to be received	$ 2,700,000,000
Number of programs under agreement | Program	5
Transaction price	$ 55,000,000
Deferred revenue, revenue recognized		5,404,000	3,277,000	9,404,000	5,660,000
Deferred revenue		30,859,000		$ 30,859,000
On Premise Software
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, practical expedient, financing component [true false]				true
Drug Discovery Services
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Milestone payment yet to be achieved				$ 1,350,000	$ 0
Revenue recognized with milestones		1,350,000	$ 0
Drug Discovery Contribution
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Deferred revenue		$ 2,887,000		$ 2,887,000
Oncology Product | Collaboration and License Agreement | BMS
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Maximum milestone payments to be received	585,000,000
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones	360,000,000
Milestone payments to be received upon achievement of certain specified commercial milestones	225,000,000
Neurology and Immunology Product | Collaboration and License Agreement | BMS
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Maximum milestone payments to be received	482,000,000
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones	257,000,000
Milestone payments to be received upon achievement of certain specified commercial milestones	$ 225,000,000